Sirapa Klinfueng

1.2k total citations
42 papers, 660 citations indexed

About

Sirapa Klinfueng is a scholar working on Infectious Diseases, Epidemiology and Hepatology. According to data from OpenAlex, Sirapa Klinfueng has authored 42 papers receiving a total of 660 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Infectious Diseases, 21 papers in Epidemiology and 13 papers in Hepatology. Recurrent topics in Sirapa Klinfueng's work include SARS-CoV-2 and COVID-19 Research (19 papers), COVID-19 Clinical Research Studies (14 papers) and Hepatitis B Virus Studies (11 papers). Sirapa Klinfueng is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (19 papers), COVID-19 Clinical Research Studies (14 papers) and Hepatitis B Virus Studies (11 papers). Sirapa Klinfueng collaborates with scholars based in Thailand, United Kingdom and United States. Sirapa Klinfueng's co-authors include Yong Poovorawan, Sompong Vongpunsawad, Thanunrat Thongmee, Preeyaporn Vichaiwattana, Nungruthai Suntronwong, Nasamon Wanlapakorn, Sumeth Korkong, Chompoonut Auphimai, Apiradee Theamboonlers and Natthinee Sudhinaraset and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Sirapa Klinfueng

39 papers receiving 647 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sirapa Klinfueng Thailand	15	349	349	207	88	69	42	660
Daixi Jiang China	14	282 0.8×	243 0.7×	134 0.6×	60 0.7×	37 0.5×	31	523
Chompoonut Auphimai Thailand	14	131 0.4×	312 0.9×	83 0.4×	102 1.2×	40 0.6×	26	438
Jingshan Zheng China	10	469 1.3×	222 0.6×	55 0.3×	213 2.4×	33 0.5×	16	607
Nawarat Posuwan Thailand	15	551 1.6×	155 0.4×	458 2.2×	25 0.3×	27 0.4×	36	699
Seyed Dawood Mousavi Nasab Iran	11	120 0.3×	293 0.8×	70 0.3×	12 0.1×	36 0.5×	33	492
Frank Kowalzik Germany	9	237 0.7×	163 0.5×	25 0.1×	65 0.7×	99 1.4×	22	492
Murray Kimmel United States	4	461 1.3×	147 0.4×	23 0.1×	111 1.3×	63 0.9×	5	604
Richard Nathan United States	6	526 1.5×	239 0.7×	23 0.1×	113 1.3×	54 0.8×	7	666
Jose Capellan Canada	4	474 1.4×	170 0.5×	22 0.1×	71 0.8×	59 0.9×	5	540
H. Engelmann Germany	6	296 0.8×	101 0.3×	42 0.2×	20 0.2×	20 0.3×	6	325

Countries citing papers authored by Sirapa Klinfueng

Since Specialization

Citations

This map shows the geographic impact of Sirapa Klinfueng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sirapa Klinfueng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sirapa Klinfueng more than expected).

Fields of papers citing papers by Sirapa Klinfueng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sirapa Klinfueng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sirapa Klinfueng. The network helps show where Sirapa Klinfueng may publish in the future.

Co-authorship network of co-authors of Sirapa Klinfueng

This figure shows the co-authorship network connecting the top 25 collaborators of Sirapa Klinfueng. A scholar is included among the top collaborators of Sirapa Klinfueng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sirapa Klinfueng. Sirapa Klinfueng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wanlapakorn, Nasamon, Jira Chansaenroj, Preeyaporn Vichaiwattana, Sirapa Klinfueng, & Yong Poovorawan. (2025). Seroprevalence of antibodies to hepatitis A, B and C viruses across all age groups in Chonburi Province, Thailand, 2022–2023. Human Vaccines & Immunotherapeutics. 21(1). 2480403–2480403.

Kanokudom, Sitthichai, Pornjarim Nilyanimit, Jiratchaya Puenpa, et al.. (2025). A comparative national survey on the gradual decline of hepatitis C virus prevalence in Thailand, 2004, 2014, and 2024. Scientific Reports. 15(1). 19794–19794.

Thongmee, Thanunrat, et al.. (2024). Seroprevalence of antibodies against varicella zoster virus across all age groups during the post-COVID-19 pandemic period in Chonburi Province, Thailand. Human Vaccines & Immunotherapeutics. 20(1). 2367283–2367283. 1 indexed citations

Suntronwong, Nungruthai, Preeyaporn Vichaiwattana, Sirapa Klinfueng, et al.. (2023). SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during the pre- and omicron-dominant wave, from January 2021 through December 2022, Thailand: A longitudinal study. PLoS ONE. 18(4). e0279147–e0279147. 6 indexed citations

Yorsaeng, Ritthideach, Nungruthai Suntronwong, Sitthichai Kanokudom, et al.. (2023). SARS-CoV-2 Antibody Dynamics after COVID-19 Vaccination and Infection: A Real-World Cross-Sectional Analysis. Vaccines. 11(7). 1184–1184. 8 indexed citations

Suntronwong, Nungruthai, Sitthichai Kanokudom, Suvichada Assawakosri, et al.. (2023). Neutralizing antibodies against Omicron BA.5 among children with infection alone, vaccination alone, and hybrid immunity. International Journal of Infectious Diseases. 134. 18–22. 4 indexed citations

Kanokudom, Sitthichai, Jira Chansaenroj, Suvichada Assawakosri, et al.. (2023). Real-World Study: Hybrid Immunity against SARS-CoV-2 Influences the Antibody Levels and Persistency Lasting More than One Year. Vaccines. 11(11). 1693–1693. 3 indexed citations

Kanokudom, Sitthichai, Jira Chansaenroj, Nungruthai Suntronwong, et al.. (2023). The Fourth Dose of mRNA COVID-19 Vaccine Following 12 Different Three-Dose Regimens: Safety and Immunogenicity to Omicron BA.4/BA.5. Vaccines. 11(3). 570–570. 7 indexed citations

Assawakosri, Suvichada, Sitthichai Kanokudom, Nungruthai Suntronwong, et al.. (2023). Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination. Heliyon. 10(1). e23892–e23892. 5 indexed citations

10.

Chansaenroj, Jira, Preeyaporn Vichaiwattana, Donchida Srimuan, et al.. (2023). Dynamics of Cytokine, SARS-CoV-2-Specific IgG, and Neutralizing Antibody Levels in COVID-19 Patients Treated with Convalescent Plasma. SHILAP Revista de lepidopterología. 11(3). 112–112. 3 indexed citations

11.

Assawakosri, Suvichada, Sitthichai Kanokudom, Nungruthai Suntronwong, et al.. (2022). Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination. The Journal of Infectious Diseases. 226(8). 1372–1381. 41 indexed citations

12.

Thongpan, Ilada, Preeyaporn Vichaiwattana, Thanunrat Thongmee, et al.. (2022). High seroprevalence of antibodies against human respiratory syncytial virus and evidence of respiratory syncytial virus reinfection in young children in Thailand. International Journal of Infectious Diseases. 125. 177–183. 8 indexed citations

13.

Assawakosri, Suvichada, Sitthichai Kanokudom, Jira Chansaenroj, et al.. (2022). Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination. International Journal of Infectious Diseases. 122. 793–801. 13 indexed citations

14.

Kanokudom, Sitthichai, Suvichada Assawakosri, Nungruthai Suntronwong, et al.. (2022). Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine. Vaccines. 10(1). 86–86. 48 indexed citations

15.

Chansaenroj, Jira, Nungruthai Suntronwong, Sitthichai Kanokudom, et al.. (2022). Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine. Vaccines. 10(7). 1071–1071. 11 indexed citations

16.

Suntronwong, Nungruthai, Ritthideach Yorsaeng, Jiratchaya Puenpa, et al.. (2022). COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron. Vaccines. 10(3). 391–391. 13 indexed citations

17.

Yorsaeng, Ritthideach, Preeyaporn Vichaiwattana, Sirapa Klinfueng, et al.. (2021). COMPARISON OF SARS-COV-2 ANTIBODY PRODUCTION BY 2-DOSE CORONAVAC, 2-DOSE VAXZEVRIA, 2-DOSE CORONAVAC-VAXZEVRIA HETEROLOGOUS VACCINATION AND POST-INFECTION. Southeast Asian Journal of Tropical Medicine and Public Health. 52(5). 689–695. 1 indexed citations

18.

Suntronwong, Nungruthai, Preeyaporn Vichaiwattana, Sirapa Klinfueng, et al.. (2021). Prevalence of antibodies against seasonal influenza A and B viruses among older adults in rural Thailand: A cross-sectional study. PLoS ONE. 16(8). e0256475–e0256475. 4 indexed citations

19.

Wasitthankasem, Rujipat, Preeyaporn Vichaiwattana, Chompoonut Auphimai, et al.. (2017). HCV core antigen is an alternative marker to HCV RNA for evaluating active HCV infection: implications for improved diagnostic option in an era of affordable DAAs. PeerJ. 5. e4008–e4008. 23 indexed citations

20.

Posuwan, Nawarat, Nasamon Wanlapakorn, Pattaratida Sa‐nguanmoo, et al.. (2016). The Success of a Universal Hepatitis B Immunization Program as Part of Thailand’s EPI after 22 Years’ Implementation. PLoS ONE. 11(3). e0150499–e0150499. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact